Hold JNJ: Unfavorable risk-reward at $270; two entry triggers defined for new capital
Maintain existing JNJ exposure at current weight; do NOT initiate new positions at $270.01. Risk-reward asymmetry is unfavorable: approximately 2% upside to 52-week high ($276.47) versus 8-10% downside to the 50 SMA ($254.83). Volume contraction for four consecutive sessions (7.84M → 7.73M → 6.48M → 6.18M) signals distribution warning. Forward 12.31 EPS depends on flawless Stelara LOE digestion, Caplyta ramp, and Intra-Cellular integration—unproven bets the market is not paying to wait for at premium levels. Structural moat thesis (0.23 beta, 64-year dividend streak, 25.7% ROE, $16.9B TTM FCF) supports holding core but does not warrant new capital deployment at 22x forward P/E with 43% embedded EPS growth assumption.
| Position | Action |
|---|---|
| New positions on pullback entry ($250-256 zone, RSI above 45, no MACD bearish crossover) | Scale in at 3-5% of portfolio with stops below $248 (200 SMA area) |
| New positions on breakout entry (daily close above $273.38 with volume above 7.5M shares) | Use stops below $265 (10-day EMA zone) |
| Existing positions approaching $276.47 with volume divergence (price up, volume down) | Reduce exposure—textbook late-stage distribution signal |
| Close below $254.83 on above-average volume | Trailing stop triggered—defensive reassessment warranted; invalidate bullish technical structure |
JNJ's earnings are re-accelerating at the exact moment the market is rewarding defensives and punishing speculation; the August pullback was absorbed, and the stock's combination of 22.0x forward P/E, 25.7% ROE, 0.231 beta, and 2.0% dividend makes it the institutional "parking spot" for durable capital—not a stock to wait on.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | $265.82 | bullish |
| close_50_sma | $254.83 | bullish |
| close_200_sma | $230.42 | bullish |
| macd | 4.11 | bullish |
| macds | 3.38 | bullish |
| macdh | +0.73 | bullish |
| rsi | 61.84 | neutral |
| atr | $5.86 | neutral |
| vwma | approximately $262.62 | bullish |
| bollinger_middle | $262.15 | bullish |
| bollinger_upper | $273.38 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed daily close above $273.38 with volume above 7.5M shares
Then: Initiate new positions with volume confirmation
↩ rebuts: “Anchoring to backward-looking P/E”
· concedes: Technicals are extended: price is 1.2% below the upper Bollinger Band; TTM P/E of 31.4 and PEG of 4.79 are indeed above historical averages; Waiting for $262–$266 zone would provide a better entry, but the pullback may never come
JNJ is a great company but not a great stock at $270, near 52-week highs, priced for perfection with unproven growth assumptions, mismatched defensive characteristics in the current macro environment, volume-diverged recovery, and multiple unpriced tail risks including talc litigation, IRA drug pricing headwinds, and integration risk on the $14.5B Intra-Cellular acquisition.
· concedes: JNJ is a great company with a real quality profile; The 43% EPS growth could materialize if LOE digestion and Caplyta ramp go as planned; JNJ won't crash here — the downside is more likely 'doing nothing' while market rotates to offensive positioning; The dividend, while below treasuries, still provides some income floor; The Q2 beat was real and showed execution capability; Some of the litigation tail risk may be priced in via Kenvue separation
→ vs conservative: Waiting for $254 pullback to 50-day SMA is wealth-destroying; JNJ has consistently rallied from $230 to $270 while waiting investors sat on sidelines
→ vs conservative: The 8-10% downside scenario requires multi-stage breakdown below 10-day EMA, Bollinger band at $262.15, MACD bearish crossover, and close below 50-day SMA — all improbable given current indicators
→ vs conservative: Conservative 3-5% portfolio sizing for a low-beta re-rating candidate underweights the opportunity in a no-cuts environment
→ vs neutral: Claim that 22x P/E is 'stretched' ignores JNJ historically trading at 18-20x in much worse operating environments; current premium is earned
→ vs neutral: Upside not capped at 2% to recent high; fundamental re-rating thesis supports meaningfully higher targets than conservative framework acknowledges
→ vs neutral: Volume contraction to 6.18 million vs 7.84 million August peak indicates supply drying up, not demand weakness — a healthy uptrend signal
→ vs neutral: Waiting for 7.5 million volume confirmation on $273.38 breakout ensures missing the move by paying 5-10% more
| bollinger_lower | $250.92 | bearish |
Support: 267.04 · 265.82 · 262.15 · 254.83 · 250.92 · 230.42 | Resistance: 273.38 · 276.47
JNJ exhibits a bullish multi-timeframe structure with a positive MA hierarchy (10 EMA $265.82 > 50 SMA $254.83 > 200 SMA $230.42). MACD is positive at 4.11 above its signal line at 3.38, and RSI of 61.84 provides upside room without being overbought. The stock is within 1.2% of the upper Bollinger Band at $273.38, creating a less attractive chase entry. Latest volume of 6.18 million is lighter than the August 18–19 advance (7.84M and 7.73M), reducing breakout quality. ATR of $5.86 suggests using ATR-adjusted stops around $264.38–$261.45 for risk management. The actionable posture is HOLD for existing positions, with new entries preferred on pullbacks to $262–$266 or confirmed breakouts above $273.38 with volume expansion.
Market Cap
$651.25 B
TTM EPS
$8.61
Forward EPS
$12.31
P/E (TTM)
31.39
Forward P/E
21.96
PEG Ratio
4.79
Price/Book
7.66
Dividend Yield
2.0%
Beta
0.231
52-Week High
$276.47
52-Week Low
$173.33
50-Day MA
$254.19
200-Day MA
$231.39
Current Price
~$270.40
TTM Revenue
~$97.9 B
Gross Margin
68%
Operating Margin
29.2%
R&D Intensity
~14.7% of revenue
2026-Q2 Revenue
$25.31 B
2026-Q2 YoY Revenue Growth
+6.6%
2026-Q2 Operating Income
$7.17 B
2026-Q2 Diluted EPS
$2.27
Total Assets
$201.1 B
Cash & ST Investments
$20.8 B
Receivables
$19.0 B
Inventory
$15.1 B
Goodwill + Intangibles
$96.7 B
Total Equity
$85.0 B
Total Debt
$49.0 B
Net Debt
$28.6 B
Net Debt/Equity
0.34x
Current Ratio
1.09
LT Debt
$37.3 B
Working Capital
$4.9 B
Tangible Book Value
-$11.7 B
Treasury Stock
~$75.9 B
Additional Paid-In Capital
~$171.7 B
Equity Growth (YoY)
+8.3%
FCF (TTM)
$16.9 B
FCF Margin
~17%
2026-Q2 Operating CF
$8.62 B
2026-Q2 CapEx
$1.32 B
2026-Q2 Free CF
$7.30 B
Annual Dividend (per share)
~$5.20/year
Annualized Dividends
~$12.6 B
Quarterly Buybacks Range
$1.9 B - $4.0 B
M&A Outflow 2025-Q2
$14.46 B
M&A Outflow 2025-Q4
$3.08 B
Debt Issuance 2026-Q1
$12.4 B
Net Margin
21.5%
ROE
25.7%
ROA
8.6%
EBITDA (TTM)
$34.9 B
EBITDA Margin
35.6%
Quarterly Tax Rate Range
12.6% - 31.2%
Quarterly Net Income Band
$5.1-$5.5 B
Goodwill
$48.5 B
Intangibles
$48.2 B
Strengths
Concerns
JNJ is a high-quality defensive compounder with re-accelerating fundamentals and a pristine balance sheet, trading within 2% of its 52-week high at $270.40. The company delivered strong 2026-Q2 results with +6.6% YoY revenue growth and $7.3 B in free cash flow, driven by its diversified Innovative Medicine and MedTech segments. Despite premium valuation (P/E 31.4, PEG 4.79, P/B 7.66) and the stock trading near resistance, the ultra-defensive profile (Beta 0.23), 25.7% ROE, 2% dividend yield, and $16.9 B TTM FCF make it ideal for long-term buy-and-hold investors who should HOLD and add on pullbacks to the 50-day MA (~$254) or 200-day MA (~$231), while new entrants should wait for a more attractive entry.
Macro: No Fed cuts priced for 2026 (85% probability, ~$7.4M traded on Polymarket); US recession at 8% (low), Japan at 41% (+15.5pp WoW), UK at 12%; Iran de-escalation supporting risk assets and oil rollover; Walmart/Amazon consumer warning is soft undercurrent; risk-on equity tape with yields rising modestly intraday.